Executive Summary
Across the seven filings, the dominant theme is governance and regulatory stress among Indian listed companies rather than clean operating momentum.
Purple Agrotech (formerly Purple Entertainment) shows the sharpest deterioration: H1 FY27 total income fell to ₹171.30 lakh from ₹2,101.10 lakh in FY26, revenue from operations was nil in both the quarter and half-year, and total assets shrank to ₹1,220.22 lakh from ₹2,109.30 lakh, with cash down to ₹65.18 lakh from ₹589.73 lakh; it is simultaneously absorbing a SEBI penalty of ₹50 lakh (stayed by SAT, paid October 7, 2026). Urja Global shows segment-wide revenue declines (EV about -43% YoY, Batteries about -53%, Renewables about -14%) alongside an auditor flagging undocumented mining investments and ₹20.34 Cr of receivables aged over 180 days, plus a ₹90 lakh SEBI penalty under appeal. Praxis Home Retail is the most distressed, with a negative net worth of ₹(10,085.14) lakh, net current liabilities of ₹8,336.52 lakh, a going-concern uncertainty, and a rights issue of up to ₹5,500 lakh being pursued. Fortis Healthcare presents mixed results: Q2 total income rose about 11.5% YoY and revenue from operations about 14%, but six-month PAT was essentially flat (₹17,769 lacs vs ₹17,697 lacs), and an overhang of SFIO, SEBI and EOW proceedings persists. Shilpa Medicare is the only clearly positive development, with NCLAT setting aside the CIRP admission against its subsidiary FTF Pharma and the company stating no quantifiable impact. Market implication: enforcement and governance overhangs are compressing valuations and liquidity in the smaller names, and investors should price in financing and regulatory-outcome risk rather than headline revenue growth.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: Insolvency · Corporate governance
Tracking the trend? Catch up on the prior India SEBI Regulatory Enforcement Actions digest from November 04, 2026.
Investment Signals (10)
- Shilpa Medicare ↓ (BULLISH)▲
NCLAT (order dated 4 Nov 2026) set aside the NCLT Ahmedabad admission of CIRP against wholly owned subsidiary FTF Pharma; company states no quantifiable impact on the listed entity
- Fortis Healthcare ↓ (BULLISH)▲
Q2 FY27 total income ₹61,091 lacs vs ₹54,823 lacs (+11.4%) and revenue from operations +14% YoY, with six-month EBITDA up to ₹33,735 lacs from ₹32,042 lacs and finance costs down to ₹9,157 lacs from ₹10,254 lacs
- Fortis Healthcare ↓ (BEARISH)▲
Q2 exceptional gain of ₹706 L from reversal of subsidiary investment impairment, but Q2 PBT before exceptional items fell 17.0% YoY on higher employee and professional fees; six-month PAT essentially flat at ₹17,769 lacs vs ₹17,697 lacs
- Purple Agrotech (Purple Entertainment) (BEARISH)▲
H1 FY27 total income ₹171.30 lakh vs ₹2,101.10 lakh for FY26 and nil revenue from operations, with cash falling to ₹65.18 lakh from ₹589.73 lakh
- Purple Agrotech (Purple Entertainment) (MIXED)▲
Borrowings reduced to ₹22.00 lakh from ₹896.25 lakh and finance costs down about 54.5% to ₹8.95 lakh in H1 FY27, signalling deleveraging, though driven by shrinking operations rather than organic repayment capacity
- Urja Global ↓ (BEARISH)▲
Consolidated revenue declined across all reported segments YoY (EV about -43%, Batteries about -53%, Renewables about -14%), with no segment showing growth
- Urja Global ↓ (MIXED)▲
Leadership changes announced with new CEO Sunil Kumar Singh effective 5 Nov 2026 and CFO Vipul Jain effective 19 Dec 2026, both to be tracked for early strategic signals
- Praxis Home Retail ↓ (BEARISH)▲
Q2 FY27 total income ₹2,619.48 lakh vs ₹2,245.51 lakh (+16.7% YoY), but loss before tax widened to ₹(1,280.15) lakh from a prior-year profit of ₹8,104.26 lakh that was driven by a one-time exceptional gain
- Praxis Home Retail ↓ (MIXED)▲
Rights issue of up to ₹5,500 lakh is the principal balance-sheet lever against net current liabilities of ₹8,336.52 lakh; execution and subscription outcome are the key variables
- Fortis Healthcare ↓ (MIXED)▲
Trade receivables rose to ₹30,794 L from ₹23,980 L at March 31, 2026 (+28%), while current ratio improved to 0.47 from 0.33, indicating liquidity improvement partly funded by receivables build-up
Risk Flags (10)
- Praxis Home Retail/Going Concern↓ [HIGH RISK]▼
Negative net worth of ₹(10,085.14) lakh, net current liabilities ₹8,336.52 lakh and half-year cash loss ₹2,155.64 lakh; auditor Singhi & Co. issued a Material Uncertainty Related to Going Concern
- Praxis Home Retail/Insolvency↓ [HIGH RISK]▼
Operational creditor Koncepts Interior (claim about ₹107 lakh) has an insolvency petition pending before NCLT Mumbai, alongside several tribunal proceedings
- Urja Global/Audit & Asset Recoverability↓ [HIGH RISK]▼
Auditor found no documentary evidence for mines investments and loans/advances (CWIP ₹46.35 Cr), with recoverability not determinable after a 2021 GST raid removed records; qualified-style limited review with extensive emphasis-of-matter paragraphs
- Urja Global/Receivables Quality↓ [HIGH RISK]▼
₹30.76 Cr receivables outstanding, of which ₹20.34 Cr aged over 180 days, plus a ₹36.46 Cr debtor set-off; a ₹28.81 Cr interest-free loan from promoter Nandanvan Commercial carries no interest since inception
- Urja Global/Regulatory & Tax↓ [MEDIUM RISK]▼
SEBI penalty of ₹90 lakh under appeal plus multiple GST and income-tax demands outstanding
- Purple Agrotech/SEBI Enforcement [HIGH RISK]▼
SEBI Final Order dated 30 Jun 2026 imposed a four-year market access restraint and ₹50 lakh penalty; SAT stayed it on 11 Sep 2026 subject to deposit, so the restraint outcome on appeal remains open
- Purple Agrotech/Earnings Quality [MEDIUM RISK]▼
Q2 FY27 PAT of ₹11.26 lakh versus ₹12.35 lakh (about -8.8%) and total assets down 42% from March 31, 2026 with no operating revenue, indicating the reported profit is not from core activity
- Fortis Healthcare/Regulatory Overhang↓ [HIGH RISK]▼
Supreme Court-directed forensic audit by Delhi High Court, SEBI show-cause and penalty proceedings, SFIO investigation and EOW complaints relating to erstwhile promoters remain unresolved
- Fortis Healthcare/Working Capital↓ [MEDIUM RISK]▼
Debtors turnover fell to 3.68 for six months from 4.25 a year earlier and allowance for doubtful receivables reached 3.78% of receivables, signalling collection stress
- Fortis Healthcare/Earnings Momentum↓ [MEDIUM RISK]▼
Net profit fell sharply to ₹130 Cr in the quarter from ₹48 Cr in the preceding quarter only on the reported basis, and Q2 PBT before exceptionals declined 17.0% YoY, showing cost pressure
Opportunities (7)
- Shilpa Medicare/Insolvency Reversal↓ (OPPORTUNITY)◆
NCLAT annulment of CIRP at FTF Pharma removes an overhang on the parent; with no quantifiable impact disclosed, the stock could re-rate as the dispute tied to the Technology Transfer Agreement is contained
- Fortis Healthcare/Operating Leverage↓ (OPPORTUNITY)◆
Revenue from operations up 14% YoY vs six-month EBITDA up about 5% suggests cost discipline is lagging; if employee and professional fee growth normalises, margin recovery is a plausible catalyst
- Fortis Healthcare/Governance Resolution↓ (OPPORTUNITY)◆
Clearance of the forensic audit, SFIO and SEBI proceedings tied to erstwhile promoters would remove a long-running discount; monitor for final orders
- Praxis Home Retail/Rights Issue Recapitalisation↓ (OPPORTUNITY)◆
A successful rights issue of up to ₹5,500 lakh would directly address negative net worth and net current liabilities; for investors with a higher risk tolerance, participation may offer entry at a restructured capital base
- Purple Agrotech/Deleveraging Clean-up (OPPORTUNITY)◆
Borrowings cut from ₹896.25 lakh to ₹22.00 lakh and SAT stay of the SEBI order allow a cleaner balance sheet; a reactivated trading or new revenue line would be a re-rating catalyst
- Urja Global/Leadership Reset↓ (OPPORTUNITY)◆
Appointment of a new CEO effective 5 Nov 2026 and CFO effective 19 Dec 2026 offers a window for management to address the auditor's qualifications; watch the next results for remediation evidence
- Fortis Healthcare/Revenue Compounding↓ (OPPORTUNITY)◆
Q2 revenue from operations grew 6.1% QoQ and 13.9% YoY, supporting a continued growth trajectory in the hospital business if sustained
Sector Themes (5)
- Governance Overhang in Small and Mid-Cap Listed Entities◆
Four of seven filings (Urja Global, Purple Agrotech, Praxis Home Retail, Fortis Healthcare) carry active SEBI, SFIO, NCLT or EOW proceedings, with penalties ranging from ₹50 lakh to ₹90 lakh; implication is persistent valuation discounts until final orders are issued
- Going-Concern and Financing Stress◆
Praxis Home Retail's negative net worth and Purple Agrotech's shrinking balance sheet (total assets -42% from March 2026) show that revenue collapse is often accompanied by liquidity compression; rights issues and promoter-related loans are the financing levers in use
- Revenue Contraction in Clean-Energy and EV Segments◆
Urja Global's EV (-43%), Battery (-53%) and Renewables (-14%) declines indicate weak demand or execution in the sector; investors should compare peers before extrapolating to the whole theme
- Receivables Build-up and Collection Risk◆
Fortis Healthcare's receivables rose 28% since March 2026 while debtors turnover declined, and Urja Global carries ₹20.34 Cr aged over 180 days; receivable quality is a common cross-company concern to screen for
- Impairment and Exceptional-Item Reliance◆
Both Fortis (₹706 L impairment reversal) and Praxis (prior-year exceptional gain) show reported profitability dependent on exceptional items; underlying operating earnings should be the valuation basis
Watch List (7)
-
Rights issue execution (up to ₹5,500 lakh) and the pending Koncepts Interior insolvency petition (about ₹107 lakh claim); watch for subscription outcome and any admission hearing dates
-
New CEO effective 5 Nov 2026 and CFO effective 19 Dec 2026; watch the next quarterly results and the response to auditor emphasis-of-matter items on mines investments and receivables
- Purple Agrotech/SAT Appeal👁
SAT stay of the SEBI order (four-year restraint, ₹50 lakh penalty, paid 7 Oct 2026) pending final appeal; watch for SAT hearing dates and any change in trading or revenue activity
-
Ongoing SFIO investigation, Delhi High Court forensic audit and SEBI show-cause proceedings; watch for final orders or hearing schedules that could move the governance discount
-
NCLAT annulment of CIRP is final unless challenged; watch for any further appeal by the operational creditor Immacule Lifesciences and the Technology Transfer Agreement dispute
-
₹90 lakh SEBI penalty and GST/income-tax demands under appeal; watch for appellate rulings and any provisioning changes in the next results
-
Allowance for doubtful receivables at 3.78% and rising trade receivables; watch the next quarter for provisioning trends and debtor-days movement
Filing Analyses
(7)
05-11-2026
Shilpa Medicare Limited disclosed that the National Company Law Appellate Tribunal (NCLAT), New Delhi, by order dated 4 November 2026, set aside the NCLT Ahmedabad Bench order dated 9 September 2026 that had admitted Corporate Insolvency Resolution Process (CIRP) proceedings against FTF Pharma Private Limited, its wholly owned subsidiary, and consequently the CIRP stands annulled. The company states there is no quantifiable impact on the listed entity from the earlier order being annulled. The appeal was filed by Mr. Abhay Sapre, a suspended director of FTF Pharma, against the operational creditor Immacule Lifesciences Private Limited.
- · NCLAT order dated 4 November 2026 in Comp. App. (AT) (Ins) No. 1781 of 2026 set aside the NCLT Ahmedabad order dated 9 September 2026 (C.P. (IB) No. 346 (Ahm) of 2025)
- · Company received the order on 5 November 2026 and disclosed it under Regulation 30 of SEBI Listing Regulations
- · Company states the appeal's underlying dispute concerns a Technology Transfer Agreement with an operational creditor, with disputed milestone payments and a disputed invoice for third-party testing
- · Annulment of CIRP is characterised by the company as having no impact on the listed entity
05-11-2026
Urja Global Limited's Board approved unaudited standalone and consolidated results for the quarter and half-year ended September 30, 2026, and appointed Mr. Sunil Kumar Singh as CEO (effective November 5, 2026) and Mr. Vipul Jain as CFO (effective December 19, 2026). The statutory auditors issued a qualified-style limited review with extensive emphasis-of-matter paragraphs covering undocumented mining investments and loans, a ₹36.46 Cr debtor set-off, ₹30.76 Cr of receivables (₹20.34 Cr aged over 180 days), a SEBI penalty of ₹90 lakh under appeal, and multiple GST and income-tax demands. Reported results are weak relative to the prior year, with mixed segment performance.
- · Consolidated revenue from Electric Vehicle segment fell about 43% YoY, Batteries about 53% and Renewable Energy about 14%, with no segment showing growth.
- · Auditor flagged no documentary evidence for mines investments and loans/advances (CWIP of ₹46.35 Cr), with recoverability not determinable after a 2021 GST raid removed records.
- · Outstanding ₹28.81 Cr loan from promoter company Nandanvan Commercial Pvt Ltd carries no interest since inception.
- · Income-tax e-proceedings notices have lapsed without replies; outstanding tax liability of ₹6.24 Cr excluding interest.
- · Multiple GST demands include a ₹44.15 Cr order (FY2018-19 to 2020-21) and ₹14.97 Cr ITC recovery, with appeals or writs pending.
- · CFO appointment takes effect only on December 19, 2026, leaving a gap after the CEO appointment.
05-11-2026
Purple Agrotech Industries Limited (formerly Purple Entertainment Limited) reported unaudited results for the quarter and half year ended September 30, 2026, with Q2 profit after tax of ₹11.26 lakh versus ₹12.35 lakh in the prior-year quarter (not a like-for-like comparison, as Q2 FY26 revenue was nil) and H1 FY27 PAT of ₹14.28 lakh versus ₹22.25 lakh in the corresponding prior-year period, a decline. Total income for H1 FY27 fell to ₹171.30 lakh from ₹2,101.10 lakh for FY26, reflecting a sharp drop in trading revenue, although revenue from operations was nil in the current quarter and half year. The company also disclosed a SEBI Final Order dated June 30, 2026 (four-year market restraint and a ₹50 lakh penalty), which SAT stayed on September 11, 2026 subject to deposit; the penalty was paid on October 7, 2026.
- · Q2 FY27 PAT of ₹11.26 lakh is versus ₹12.35 lakh in Q2 FY26, a decline of about 8.8%, which the summary does not state.
- · Finance costs for H1 FY27 were ₹8.95 lakh, down from ₹19.67 lakh in H1 FY26, a decline of about 54.5%.
- · Cash and cash equivalents fell to ₹65.18 lakh at Sep 30, 2026 from ₹589.73 lakh at March 31, 2026, and borrowings fell from ₹896.25 lakh to ₹22.00 lakh.
- · Trade receivables declined to ₹508.79 lakh from ₹606.59 lakh, and inventories of ₹47.79 lakh appeared against nil at March 31, 2026.
- · Net worth (shareholders' funds) rose to ₹1,042.12 lakh from ₹1,027.85 lakh, reflecting the H1 profit.
05-11-2026
Purple Agrotech Industries Limited (formerly Purple Entertainment Limited) reported unaudited results for the quarter and half year ended September 30, 2026, with Q2 FY27 total income of ₹25.16 lakh versus ₹146.14 lakh in the immediately preceding quarter, and profit after tax of ₹11.26 lakh versus ₹3.02 lakh; however, revenue from operations was nil in the current quarter compared with ₹141.49 lakh in the prior quarter, and the year-ago quarter also showed nil revenue, with profit after tax of ₹12.35 lakh. The company also disclosed a SEBI Final Order dated June 30, 2026 imposing a four-year market access restraint and a ₹50 lakh penalty, which SAT stayed on September 11, 2026 subject to deposit; the penalty was paid on October 7, 2026.
- · Total income for the half year ended September 30, 2026 was ₹171.30 lakh versus ₹2,101.10 lakh for the year ended March 31, 2026, while half-year profit after tax was ₹14.28 lakh versus ₹16.45 lakh for FY26 (audited).
- · Half-year revenue from operations was nil versus ₹141.49 lakh in the corresponding prior half year.
- · Total assets declined to ₹1,220.22 lakh from ₹2,109.30 lakh at March 31, 2026, and cash and cash equivalents fell to ₹65.18 lakh from ₹589.73 lakh, with borrowings reduced to ₹22.00 lakh (non-current) from ₹896.25 lakh combined.
- · Shareholders' funds rose to ₹1,042.12 lakh from ₹1,027.85 lakh, with other equity at ₹177.52 lakh versus ₹163.25 lakh.
- · Inventories of ₹47.79 lakh appeared on the balance sheet for the first time, reflecting a stock-in-trade change in the quarter.
- · The SEBI order also restrained the company from accessing securities markets and dealing in securities for four years; SAT's stay was conditional on full penalty deposit, which was completed on October 7, 2026.
- · Statement figures are in ₹ lakh (₹10 lakh = ₹0.1 crore); equity share capital is unchanged at ₹864.60 lakh (face value ₹10 per share).
05-11-2026
Fortis Healthcare reported unaudited standalone results for the quarter and six months ended September 30, 2026, with Q2 FY27 total income of ₹61,091 lacs (up from ₹54,823 lacs in the prior-year quarter) and revenue from operations of ₹51,941 lacs (up 14% YoY from ₹45,581 lacs), though revenue was up only 6% QoQ from ₹48,945 lacs. Net profit from continuing operations rose to ₹12,991 lacs in the quarter versus ₹12,509 lacs a year earlier, but six-month PAT was essentially flat at ₹17,769 lacs against ₹17,697 lacs, and EBITDA for the six months grew to ₹33,735 lacs from ₹32,042 lacs. The filing also carries ongoing governance and regulatory overhangs: the Supreme Court-directed forensic audit by the Delhi High Court, SEBI show-cause and penalty proceedings, an SFIO investigation, and EOW complaints relating to erstwhile promoters.
- · Six-month total income rose to ₹111,928 lacs from ₹102,127 lacs, while six-month other income fell to ₹11,042 lacs from ₹13,243 lacs.
- · Total expenses for the six months rose to ₹93,442 lacs from ₹86,203 lacs, and finance costs declined to ₹9,157 lacs from ₹10,254 lacs.
- · Basic and diluted EPS for the six months was ₹2.35, versus ₹2.34 in the prior-year period.
- · Trade receivables increased to ₹30,794 lacs from ₹23,980 lacs as of March 31, 2026, and allowance for doubtful receivables rose to 3.78% of receivables for the six months from 2.11% a year earlier.
- · Debtors turnover fell to 3.68 for the six months from 4.25, and the current ratio improved to 0.47 from 0.41.
- · Net worth stood at ₹940,223 lacs, and the company sought to recover ₹40,300 lacs plus interest from erstwhile promoters under SEBI directions.
- · The Delhi High Court ordered a forensic audit on August 31, 2026, which the Supreme Court allowed to proceed on September 25, 2026.
- · Management believes no adjustment is required to the results for the Fortis brand trademark and SRL brand matters, which remain subject to legal proceedings.
- · Under Ind AS 19, a one-time ₹1,035 lacs impact from the New Labour Codes was recognised as an exceptional item in FY26.
05-11-2026
Fortis Healthcare reported unaudited standalone results for Q2 FY27 (quarter ended September 30, 2026) with total income of ₹611 Cr (vs ₹548 Cr in Q2 FY26, up 11.5%) and net profit of ₹130 Cr (vs ₹125 Cr, up 3.9%), though net profit fell sharply from ₹48 Cr in the preceding quarter. Revenue from operations rose 13.9% YoY to ₹519 Cr, but sequential growth was 6.1%, and Q2 profit before tax excluding exceptional items declined 17.0% YoY on higher employee and professional fees. The filing also continues to disclose the ongoing SFIO/SEBI investigations and related legal proceedings concerning erstwhile promoters, with management stating no material further impact is expected.
- · Exceptional gain of ₹706 L in Q2 FY27 from reversal of impairment in subsidiary investments, versus ₹2,183 L in Q2 FY26
- · Trade receivables rose to ₹30,794 L from ₹23,980 L at March 31, 2026, while allowance for doubtful receivables reached 3.78% of receivables for six months
- · Current ratio improved to 0.47 from 0.33 at March 31, 2026, while debtors turnover declined to 3.68 for six months from 4.25 a year earlier
- · Net cash from operating activities rose to ₹16,907 L for six months from ₹2,489 L a year earlier, but net cash used in financing was ₹24,040 L
- · Ongoing SEBI penalty appeals (₹100 L and ₹50 L on Company and FHsL; ₹100 L on EHIRCL) remain pending before SAT Mumbai
- · Brand License related claim by Headway Brands ex-director seeks ~₹362 Cr, pending before Delhi High Court
05-11-2026
Praxis Home Retail Limited's Board approved unaudited results for the quarter and half year ended September 30, 2026, showing a half-year cash loss of ₹2155.64 lakh and a negative net worth of ₹(10,085.14) lakh, with a Material Uncertainty Related to Going Concern flagged by the auditor, Singhi & Co. Total income for Q2 FY27 was ₹2,619.48 lakh versus ₹2,245.51 lakh in Q2 FY26 (up ~16.7%), but loss before tax widened to ₹(1,280.15) lakh from a prior-year profit of ₹8,104.26 lakh, which was driven by a one-time exceptional gain. The company is pursuing a rights issue of up to ₹5,500 lakh and faces several insolvency and tribunal proceedings.
- · Net current liabilities of ₹8,336.52 lakh as of September 30, 2026
- · Auditor issued a Material Uncertainty Related to Going Concern with an unmodified conclusion
- · Insolvency petition by operational creditor Koncepts Interior (claim ~₹107 lakh) pending before NCLT Mumbai
- · GST Appellate Tribunal ordered deposit of ₹367.88 lakh profiteered amount with interest at 18%; company evaluating appeal
- · NCLT order against company re Ojas Tradelease lease; ₹1,955 lakh claimed, under appeal before NCLAT
- · NCRPs of ₹630 lakh issued to Future Enterprises Ltd remain unredeemed since December 8, 2022
- · Promoter reclassification request to public category returned by NSE; company resubmitting documents
- · Stock options of 22,05,000 granted to eligible employees on August 7, 2026
Get daily alerts with 10 investment signals, 10 risk alerts, 7 opportunities and full AI analysis of all 7 filings
₹500/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: India SEBI Regulatory Enforcement Actions
November 03, 2026
India SEBI Regulatory Enforcement Actions — November 03, 2026
November 02, 2026
India SEBI Regulatory Enforcement Actions — November 02, 2026
October 31, 2026
India SEBI Regulatory Enforcement Actions — October 31, 2026
October 30, 2026
India SEBI Regulatory Enforcement Actions — October 30, 2026
🇮🇳 More from India
View all →November 06, 2026
India Pre-Market Regulatory Roundup — November 06, 2026
India Pre-Market Regulatory Roundup
November 06, 2026
India Quarterly Results BSE NSE Announcements — November 06, 2026
India Quarterly Results BSE NSE Announcements
November 06, 2026
India Upcoming Corporate Actions BSE NSE — November 06, 2026
India Upcoming Corporate Actions BSE NSE
November 06, 2026
India RBI Monetary Policy Repo Rate Decisions — November 06, 2026
India RBI Monetary Policy Repo Rate Decisions